TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9594199

Group type: EXPERIMENTAL
Intervention: Nonwashed shed mediastinal blood (group 1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Banked blood (group 2)
Number of subjects: 42
Study: 1343614

Group type: EXPERIMENTAL
Intervention: Early surfactant (colfosceril palmitate, Exosurf)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Selective surfactant (air placebo)
Number of subjects: 420
Study: 6504920

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30837403

Group type: EXPERIMENTAL
Intervention: Zirconium oxide sand-blasting (Group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Zirconia bonded porcelain (Group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hot-etching solution (Group C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-treatment zirconia (Group D)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-treatment nickel-chromium alloy (Group E)
Number of subjects: 50
Study: 29898704

Group type: COMPARATOR
Intervention: Continuous cycling exercise at moderate intensity (experiment A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Interval cycling exercise plus Flutter(R) (experiment B)
Number of subjects: 15
Study: 27882012

Group type: EXPERIMENTAL
Intervention: Resistance Training Group (RTG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 14
Study: 25454968

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 40
Study: 22023910

Group type: EXPERIMENTAL
Intervention: Experimental food preparers attended 8 weekly interactive lessons
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control food preparers received 8 weekly mailings with similar recipes and handouts
Number of subjects: 100
Study: 19616304

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 17590217

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Aliskiren 600 mg
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 569

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study: 15714224

Group type: EXPERIMENTAL
Intervention: Melatonin (0.5 mg at 1700 h for 6 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 29
Study: 12357730

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 0
Study: 9788075

Group type: EXPERIMENTAL
Intervention: Event-related functional magnetic resonance imaging (ER-fMRI)
Number of subjects: 0
Study: 9101094

Group type: EXPERIMENTAL
Intervention: Continuous dobutamine infusion (6 micrograms/kg/min from 10 minutes before induction of anaesthesia till the fifth postoperative hour)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no dobutamine infusion)
Number of subjects: 12
Study: 2649996

Group type: EXPERIMENTAL
Intervention: Single-dose piperacillin
Number of subjects: 214

Group type: COMPARATOR
Intervention: Triple-dose cefoxitin
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Postoperative anemia
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 214
Study: 31148908

Group type: EXPERIMENTAL
Intervention: Antireflux plastic stent (ARPS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Traditional plastic stent (TPS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ARPS
Number of subjects: 38

Group type: COMPARATOR
Intervention: TPS
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ARPS and TPS
Number of subjects: 38
Study: 28253257

Group type: EXPERIMENTAL
Intervention: Health warning covering 25% of a cigarette pack
Number of subjects: 5014

Group type: EXPERIMENTAL
Intervention: Health warning covering 50% of a cigarette pack
Number of subjects: 5014

Group type: EXPERIMENTAL
Intervention: Health warning covering 75% of a cigarette pack
Number of subjects: 5014
Study: 26283175

Group type: EXPERIMENTAL
Intervention: Haemonetics MCS(®) + cell separator
Number of subjects: 526
Study: 23722616

Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol 110 μg/glycopyrronium 50 μg)
Number of subjects: 2144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2144
Study: 21385863

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg daily
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 19663520

Group type: EXPERIMENTAL
Intervention: parecoxib followed by valdecoxib
Number of subjects: 1062

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1062
Study: 16505409

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 400 mg intramuscularly (single dose)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Venlafaxine 37.5 mg per day for one week, then 75 mg per day
Number of subjects: 218
Study: 12765455

Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 207
Study: 10871979

Group type: EXPERIMENTAL
Intervention: Fast titration (every 2 weeks)
Number of subjects: 2935

Group type: COMPARATOR
Intervention: Slow titration (every 6 weeks)
Number of subjects: 2935
Study: 9201043

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 to 200 micrograms/kg/min) administered to increase cardiac index and DO2 until all therapeutic goals were achieved.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group received dobutamine only if cardiac index was < 2.8 L/min/m2.
Number of subjects: 78
Study: 8253948

Group type: EXPERIMENTAL
Intervention: Co-culture with a confluent monolayer of Vero cells
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard culture without Vero cells
Number of subjects: 100
Study: 3942892

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30335633

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27751960

Group type: EXPERIMENTAL
Intervention: tDCS SHOULDER montage
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: tDCS HEAD montage
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (SHAM)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All conditions (including CON and SHAM)
Number of subjects: 9
Study: 24894310

Group type: EXPERIMENTAL
Intervention: Integrated mental health care programme
Number of subjects: 250

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 250
Study: 24904785

Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol the night before surgery
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol on the day of surgery
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol the night and on the day of surgery
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 20147743

Group type: EXPERIMENTAL
Intervention: Doxorubicin-cyclophosphamide (AC) followed by docetaxel (Doc)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Doxorubicin-pemetrexed (AP) followed by docetaxel (Doc)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Both treatment arms combined
Number of subjects: 257
Study: 18580181

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with a 1.5 mg/kg intravenous bolus in 10 min followed by a 1.5 mg . kg . h intravenous infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study: 16086467

Group type: EXPERIMENTAL
Intervention: Conventional Medicine (CM) interventions
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Complementary and Alternative Medicine (CAM) interventions
Number of subjects: 662
Study: 12461659

Group type: EXPERIMENTAL
Intervention: Combination of azathioprine and prednisone (NoCsA group, n=58)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cyclosporine, azathioprine, and prednisone (CsA group, n=59)
Number of subjects: 117
Study: 10066996

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Younger normal control children (Control)
Number of subjects: 0
Study: 8822109

Group type: EXPERIMENTAL
Intervention: Gallbladder carcinoma and adenoma
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Common bile duct carcinoma
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ampullary carcinoma
Number of subjects: 45

Group type: COMPARATOR
Intervention: Gallbladder dysplasia
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chronic cholecystitis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ampullary carcinoma in situ (CIS)
Number of subjects: 45
Study: 2041848

Group type: EXPERIMENTAL
Intervention: Modified breast biopsy technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manufacturer's method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Third technique
Number of subjects: 40
Study: 7012883

Group type: EXPERIMENTAL
Intervention: High dose physostigmine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 9
Study: 30669360

Group type: EXPERIMENTAL
Intervention: Tetracenomycin X (Tcm X)
Number of subjects: 0
Study: 28688497

Group type: EXPERIMENTAL
Intervention: Osteoporosis prevention education and counseling program (4-week education + 24-week counseling)
Number of subjects: 73
Study: 25323219

Group type: EXPERIMENTAL
Intervention: Eszopiclone (3 mg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 23561637

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation at a dose of 1000 U/day for 12 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 47
Study: 21289621

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 209

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 209
Study: 19231253

Group type: EXPERIMENTAL
Intervention: ePTFE graft
Number of subjects: 228

Group type: COMPARATOR
Intervention: Dacron graft
Number of subjects: 228
Study: 16849623

Group type: EXPERIMENTAL
Intervention: pegaptanib 0.3 mg intravitreous injection every 6 weeks for 48 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: sham injection (placebo)
Number of subjects: 0
Study: 15545697

Group type: EXPERIMENTAL
Intervention: Foam composite dressing
Number of subjects: 107

Group type: COMPARATOR
Intervention: Hydrocellular foam dressing
Number of subjects: 107
Study: 11747282

Group type: EXPERIMENTAL
Intervention: Combined glucose plus fructosamine testing group (11 patients)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Glucose-only testing group (14 patients)
Number of subjects: 25
Study: 9355897

Group type: EXPERIMENTAL
Intervention: Troponin T (≤0.10 μg/L)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Troponin I (>2.0 μg/L)
Number of subjects: 516
Study: 8221482

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy schedule of 4000 cGy in 15 or 16 fractions over 3 weeks plus a local boost of 1250 cGy to the primary site in 5 fractions over 1 week
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy schedule of 4000 cGy in 15 or 16 fractions over 3 weeks plus a local boost of 1000 cGy to the primary site in 4 or 5 fractions over 1 week
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy schedule of 5000 cGy in 25 fractions to the whole breast in 5 weeks, without a boost
Number of subjects: 551
Study: 3713154

Group type: EXPERIMENTAL
Intervention: Plyometric training (3 sets of 10 depth jumps, 3 days/week for 12 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Regular basketball training (control group)
Number of subjects: 26
Study: 31738447

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 26
Study: 29198641

Group type: EXPERIMENTAL
Intervention: HED-SMART (self-management training program)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 235
Study: 26535563

Group type: EXPERIMENTAL
Intervention: Transnasal endosheath endoscopy (TEE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard endoscopy
Number of subjects: 25
Study: 23578719

Group type: EXPERIMENTAL
Intervention: QCT-derived structural geometry measurements
Number of subjects: 237

Group type: COMPARATOR
Intervention: DXA-derived structural geometry measurements
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Cross-calibration using 4 measures (areal bone mineral density, W, standard deviation of normalized mineral mass projection profile distribution, displacement between center of mineral mass and geometric center)
Number of subjects: 237
Study: 23025450

Group type: EXPERIMENTAL
Intervention: Kali phos 6x
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 21388579

Group type: EXPERIMENTAL
Intervention: Rivastigmine (3 mg twice a day, for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rehabilitation treatment only (No-RIV)
Number of subjects: 20
Study: 18663301

Group type: EXPERIMENTAL
Intervention: 1.25% fluoride gel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.5% fluoride gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 36
Study: 15673379

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of atrial fibrillation (AF)
Number of subjects: 45
Study: 12853193

Group type: EXPERIMENTAL
Intervention: Carvedilol (target dose 25 mg twice daily)
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Metoprolol (target dose 50 mg twice daily)
Number of subjects: 3029
Study: 11173778

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 14
Study: 9009677

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid for 14 days/amoxycillin 1000 mg bid for 14 days/tinidazole 500 mg bid for 14 days (Group A)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid for 14 days/amoxycillin 1000 mg bid for 14 days (Group B)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid for 14 days/azithromycin 500 mg/day for 3 days for 2 consecutive weeks (Group C)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day for 7 days/clarithromycin 250 mg bid for 7 days/tinidazole 500 mg bid for 7 days (Group D)
Number of subjects: 132
Study: 1386523

Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg
Number of subjects: 982

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 982
Study: 6828338

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 600 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acetaminophen 600 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lactose (placebo)
Number of subjects: 25
Study: 30829714

Group type: EXPERIMENTAL
Intervention: Risk score model for predicting cardiac rupture after acute myocardial infarction
Number of subjects: 577
Study: 30115454

Group type: EXPERIMENTAL
Intervention: Supraclavicular radiotherapy
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Internal mammary node radiotherapy
Number of subjects: 812

Group type: COMPARATOR
Intervention: No internal mammary node radiotherapy
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Age < 40 years
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: > T1 stage
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Negative hormone receptor status
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Internal mammary radiotherapy
Number of subjects: 812
Study: 27126725

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 616
Study: 24463933

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome score (MetS score)
Number of subjects: 3855
Study: 22392934

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: No neoadjuvant therapy (Control)
Number of subjects: 40
Study: 19158191

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5-25 mg/d)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Spironolactone (50-75 mg/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 23
Study: 17229249

Group type: EXPERIMENTAL
Intervention: Metformin plus pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 0
Study: 16113372

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Baseline IOP
Number of subjects: 72

Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 72
Study: 11748600

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Prolonged Exposure (PE)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 22

Group type: COMPARATOR
Intervention: PE
Number of subjects: 22
Study: 9779521

Group type: EXPERIMENTAL
Intervention: Pergolide 0.25 mg at bedtime
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7863254

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg/day for one year
Number of subjects: 581

Group type: COMPARATOR
Intervention: Control group (no regular treatment)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg/day
Number of subjects: 581
Study: 2511913

Group type: EXPERIMENTAL
Intervention: sublingual nitroglycerin tablets
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: quickly dissolving nitroglycerin compound
Number of subjects: 20
Study: 30975672

Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (HT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard medical treatment (SMT)
Number of subjects: 100
Study: 28301428

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) treatment, open-label induction at weeks 0 and 2 by body weight (≥40 kg: 160 mg and 80 mg; <40 kg: 80 mg and 40 mg), followed by randomized double-blind dosing (high or low dose every other week) to week 52.
Number of subjects: 0
Study: 25082072

Group type: EXPERIMENTAL
Intervention: Membrane sweeping (swept)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Membrane sweeping (swept) with ARM and oxytocin
Number of subjects: 800
Study: 24325112

Group type: EXPERIMENTAL
Intervention: Furosemide 0.05 mg/kg (F0.5)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Furosemide 0.1 mg/kg (F1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 120
Study: 22136978

Group type: EXPERIMENTAL
Intervention: Amlodipine/losartan 5/50 mg fixed-dose combination
Number of subjects: 185

Group type: COMPARATOR
Intervention: Amlodipine 10 mg monotherapy
Number of subjects: 185
Study: 19338704

Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Group (FVG)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 209
Study: 17326994

Group type: EXPERIMENTAL
Intervention: Serum total cholesterol (TC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia prevalence
Number of subjects: 5
Study: 15277147

Group type: EXPERIMENTAL
Intervention: Fat plus 75 g oligosaccharides
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fat plus 50 g sodium caseinate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fat alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of fat, oligosaccharides, and casein
Number of subjects: 24
Study: 12066001

Group type: EXPERIMENTAL
Intervention: Stapling
Number of subjects: 42

Group type: COMPARATOR
Intervention: Suturing
Number of subjects: 42
Study: 9649101

Group type: EXPERIMENTAL
Intervention: Early postoperative oral feeding
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional postoperative oral feeding
Number of subjects: 200
Study: 7862856

Group type: EXPERIMENTAL
Intervention: Nicotine (15 micrograms/kg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nicotine + Caffeine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2521699

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (3 mg/kg/wk)
Number of subjects: 40
Study: 124247

Group type: EXPERIMENTAL
Intervention: 1% spray solution
Number of subjects: 594

Group type: COMPARATOR
Intervention: 1% milk
Number of subjects: 594

Group type: COMPARATOR
Intervention: 1% solution
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 594
Study: 30458639

Group type: EXPERIMENTAL
Intervention: Kinesio taping application from origin to insertion (OI group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No kinesio taping (control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Kinesio taping application from insertion to origin (IO group)
Number of subjects: 45
Study: 28230615

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1000 mg every 6 hours for 24 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (100 mL every 6 hours for 24 hours)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen and Placebo
Number of subjects: 100
Study: 25487613

Group type: EXPERIMENTAL
Intervention: Droxidopa (100-600 mg thrice-daily)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Droxidopa
Number of subjects: 171
Study: 23594436

Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin (SHBG)
Number of subjects: 2816
Study: 21830512

Group type: EXPERIMENTAL
Intervention: 12 dB manipulation of HRTF frequency bands
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 18 dB manipulation of HRTF frequency bands
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0 dB manipulation of HRTF frequency bands
Number of subjects: 32